AstraZeneca is trading 7.02% up now at $186.65 after third-quarter revenue and core earnings beat forecasts.
- On October 30, revenue reached $16.21 billion and core earnings per share were $2.79, both ahead of forecasts.
- The company announced a savings plan targeting about $1.5 billion annually while maintaining its 2026 outlook; Reuters said the results and plan sparked the strongest one-day share rally in a year.
- Shares rose 2.88% on October 29 before gaining further during October 30 trading. Broader healthcare strength provided context, but company news were the more direct explanation.